233 related articles for article (PubMed ID: 7995014)
1. Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors.
Youdim MB; Finberg JP
Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):725-33. PubMed ID: 7995014
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Youdim MB
J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
[TBL] [Abstract][Full Text] [Related]
3. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
4. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
Youdim MB; Tipton KF
Parkinsonism Relat Disord; 2002 Mar; 8(4):247-53. PubMed ID: 12039419
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Riederer P; Youdim MB
J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and clinical implications of MAO-B inhibitors.
Yu PH
Gen Pharmacol; 1994 Dec; 25(8):1527-39. PubMed ID: 7721026
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of selegiline.
Gerlach M; Youdim MB; Riederer P
Neurology; 1996 Dec; 47(6 Suppl 3):S137-45. PubMed ID: 8959982
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
9. Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.
Wu RM; Chen RC; Chiueh CC
Ann N Y Acad Sci; 2000; 899():255-61. PubMed ID: 10863544
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
11. The molecular pharmacology of L-deprenyl.
Gerlach M; Riederer P; Youdim MB
Eur J Pharmacol; 1992 Jun; 226(2):97-108. PubMed ID: 1639115
[TBL] [Abstract][Full Text] [Related]
12. Biochemical actions of l-deprenyl (selegiline).
Lange KW; Riederer P; Youdim MB
Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):734-41. PubMed ID: 7995015
[TBL] [Abstract][Full Text] [Related]
13. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
Klegeris A; McGeer PL
Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
[TBL] [Abstract][Full Text] [Related]
14. Selegiline: a molecule with innovative potential.
Tábi T; Vécsei L; Youdim MB; Riederer P; Szökő É
J Neural Transm (Vienna); 2020 May; 127(5):831-842. PubMed ID: 31562557
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
[TBL] [Abstract][Full Text] [Related]
16. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
Gerlach M; Desser H; Youdim MB; Riederer P
J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective actions of selegiline.
Ebadi M; Sharma S; Shavali S; El Refaey H
J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
[TBL] [Abstract][Full Text] [Related]
18. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
Severina IS
Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
[TBL] [Abstract][Full Text] [Related]
20. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
